Full-Time

Agent Harness Engineer

Updated on 8/1/2026

Axiom

Axiom

11-50 employees

AI-driven hepatotoxicity risk assessment platform

No salary listed

San Francisco, CA, USA

In Person

Category
DevOps & Infrastructure (1)
Required Skills
FastAPI
Python
React.js
Machine Learning
Data Engineering
Docker
Terraform
Observability
Reinforcement Learning

Get referred to Axiom

See people who can refer or advise you

Requirements
  • The engineer must be proficient with Python, Modal, DuckDB, FastAPI, Docker, containerization, and Terraform.
  • The engineer must have built with large language model APIs and shipped agentic systems involving tool use, loops, and debugging.
  • The engineer must have built bespoke evaluation, monitoring, and reinforcement learning environment observability tooling using SvelteKit, Svelte 5, or React.
  • The engineer must be able to tackle deep technical challenges and ship simple, clean, maintainable code.
  • The engineer must have infrastructure, platform, data, or developer-tools depth and experience with production systems.
  • The engineer must build measurement alongside features and assess whether systems are working.
  • The engineer must understand agent failure traces and care about reliability in environments used for evaluation and training data.
  • The engineer must be able to identify what agents need to perform better work.
  • The engineer must be comfortable solving technically sophisticated problems in a discipline with no established playbook.
  • The engineer must have an engineering or tinkering mindset and be able to investigate current methods and practices.
  • The engineer must be able to learn domain experts' standards of quality and translate them into systems.
Responsibilities
  • Own the scaffolding, tooling, and infrastructure that turn frontier models into agents capable of long-horizon scientific analysis.
  • Build pipelines, storage, and systems for runtime context, agent trajectories, evaluation results, and training data.
  • Build sandboxed execution environments with instant spin-up and tear-down that are sufficiently reproducible and deterministic for evaluations and reinforcement learning.
  • Design and run offline evaluation suites, production-trace test cases, large language model judge pipelines, and regression gates.
  • Work with domain experts to encode their judgment into rubrics, golden sets, and review workflows.
  • Build tools that enable agents to perform better work and evaluate new methods, protocols, and patterns for adoption.
  • Make every agent run observable and replayable by tracing model calls, tool calls, and state transitions and building debugging tools.
  • Engineer memory, compaction, retrieval, and recovery so long-horizon agent runs remain coherent across extended runs and crashes.
  • Own retries, budget caps, stop conditions, output verification, permissions, and guardrails for agent execution.
  • Support machine learning research with environments, reward instrumentation, and rollout infrastructure for reinforcement learning on agentic tasks.

Axiom Bio uses machine learning and biochemistry to predict drug-induced liver toxicity. Its platform analyzes a molecule’s structure with AI models trained on the world’s largest proprietary dataset of human toxicity data, derived from screening over 115,000 small molecules on primary human liver cells and paired with pharmacokinetic and clinical outcome data. The system can reveal mechanisms behind toxicity, such as mitochondrial disruption, ER stress, and reactive oxygen species formation, and it outputs risk assessments for hepatotoxicity to help researchers de-risk drug development. The service is designed to be cheaper and faster than lab testing—costing roughly $100–$450 per compound compared with $3,000–$15,000 for traditional experiments—and it aims to replace animal testing with in-silico predictions. Axiom’s goal is to enable safer, more efficient drug development by providing accurate, mechanism-informed toxicity predictions to pharmaceutical and biotech clients.

Company Size

11-50

Company Stage

Seed

Total Funding

$15M

Headquarters

San Francisco, California

Founded

2024

Get referred to Axiom

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Expand from liver into kidney and cardiac safety screens.
  • Sell DILI-risk triage during lead optimization to pharma teams.
  • Capture customers with cheaper, faster predictions than physical experiments.

What critics are saying

  • Integrated rivals like Recursion can bundle AI toxicity into broader contracts.
  • Proprietary dataset moat weakens if competitors match human-cell scale.
  • Heavy wet-lab curation and small seed capital constrain expansion and validation.

What makes Axiom unique

  • Built a proprietary human-to-clinical toxicity dataset with 115,000+ molecules.
  • Uses mechanistic AI to explain mitochondrial toxicity, ER stress, and ROS.
  • Focuses on clinically relevant hepatotoxicity, not generic cell-viability scoring.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%